Oral tirzepatide reviews: what does the evidence show?

Is there a licensed oral tirzepatide you can actually take in the UK right now?

No. This is a question our prescribers hear most weeks, and the honest answer is straightforward: in the UK, tirzepatide is licensed exclusively as a subcutaneous injection, the Mounjaro KwikPen, available in six strengths from 2.5 mg up to 15 mg. The MHRA has not granted approval to any oral tirzepatide product. That means reviews you may have read online do not reflect a medicine you can legitimately obtain from a UK pharmacy today.

Eli Lilly is conducting phase 3 trials on an oral tirzepatide formulation, and early data from those trials have appeared in scientific literature and the press. That is the most likely source of the reviews in question. Trial-stage findings are preliminary by definition: they tell us what happened under controlled conditions with selected participants, not how a product performs across a general population once licensed and in everyday use. The tirzepatide page covers the full clinical profile of the licensed injectable form.

It is also worth knowing that confusion sometimes arises with Wegovy tablets (oral semaglutide) which the MHRA did approve in June 2026, making it the first oral GLP-1 medicine licensed for weight management in the UK. Semaglutide and tirzepatide work differently: semaglutide targets one receptor, tirzepatide targets two. If you have been reading reviews of an oral weight-loss tablet, you may be reading about the Wegovy pill rather than tirzepatide at all.

What does trial-stage evidence on oral tirzepatide suggest, and how cautiously should we read it?

Eli Lilly's SURPASS-ORAL and related studies have shown that oral tirzepatide can meaningfully reduce body weight in adults with type 2 diabetes, with GI tolerability that mirrors the injectable form. Some analyses have shown weight reductions in the range seen with moderate doses of injectable tirzepatide, though direct comparisons are complicated by differing populations and endpoints. The injectable form's SURMOUNT-1 trial (published in the New England Journal of Medicine) reported an average body-weight reduction of around 20–21% at 15 mg over 72 weeks, the benchmark against which any oral formulation will eventually be measured.

Phase 3 trial data is genuinely informative, but it is not the same as a licensed, approved medicine with a published Summary of Product Characteristics, a patient information leaflet, and post-market surveillance behind it. Reviews based on trial data may reflect carefully selected cohorts, specific doses not available commercially, and conditions that do not replicate real-world use. Treat them as directional evidence rather than settled clinical fact.

The tirzepatide review page covers what the published evidence on the injectable form currently shows for those who want to explore the licensed medicine's track record more deeply.

What about drops or liquid tirzepatide, are those the same as oral tirzepatide reviews describe?

Some people searching for oral tirzepatide end up looking at tirzepatide drops or tirzepatide oral solutions. These are compounded preparations (mixed outside the licensed supply chain) and they are not approved by the MHRA. The MHRA has been clear that GLP-1 medicines must come through the licensed supply chain, and has seized large quantities of counterfeit and unlicensed weight-loss preparations in recent enforcement actions. Reviews of tirzepatide drops and tirzepatide oral solution reviews describe products that sit outside UK regulatory approval entirely.

Unlicensed preparations have not undergone the stability, purity and bioavailability testing that Mounjaro has. The concentration may be wrong. The excipients may cause unexpected reactions. There is no patient information leaflet, no prescriber oversight built into the supply, and no Yellow Card history to draw on. For the sake of completeness: if you encounter a seller offering liquid tirzepatide without the requirement for a prescription from a registered prescriber, that absence of clinical oversight is itself a serious red flag. Report suspect sellers at the MHRA's Yellow Card site.

The relevant comparison, for anyone weighing up oral options that are actually available and licensed, is the Wegovy tablet, oral semaglutide at 25 mg maintenance dose. A look at Mounjaro reviews from people already on the licensed injectable may also give a more grounded picture than trial-stage oral data.

If oral tirzepatide is not available yet, what are the licensed options right now?

Two GLP-1 weight-loss medicines are currently licensed and dispensed in the UK: the Mounjaro KwikPen (tirzepatide, injectable, once weekly) and Wegovy (semaglutide, available as both a once-weekly injection and, from June 2026, as a daily tablet). Both require a prescription following a clinical assessment. Both are licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, raised cholesterol, or obstructive sleep apnoea. NICE has appraised both, with recommendations detailed in TA1026 for tirzepatide.

The Mounjaro price comparison page sets out the cost context for the injectable if you are weighing up private treatment. If you want to understand the broader weight-loss treatment landscape before deciding, that page covers all the licensed options side by side. When oral tirzepatide does reach UK approval, the regulatory pathway will run through the MHRA and then likely a NICE appraisal, the same process every licensed weight-loss medicine goes through. Until that happens, reviews of it remain reviews of a medicine not yet available here.